SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Coloplast A/S CLPBF OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • DK • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Coloplast A/S (CLPBF) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $65.31. It has a SharesGrow Score of 79/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Financials: revenue is $27.8B, +7.3%/yr average growth. Net income is $3.6B, growing at -7%/yr. Net profit margin is 13% (healthy). Gross margin is 65.1% (-3.7 pp trend).

Balance sheet: total debt is $22.6B against $16.1B equity (Debt-to-Equity (D/E) ratio 1.4, moderate). Current ratio is 1.61 (strong liquidity). Debt-to-assets is 46.8%. Total assets: $48.3B.

Analyst outlook: 1 / 1 analysts rate CLPBF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 83/100 (Pass), Moat 75/100 (Pass), Future 100/100 (Pass), Income 55/100 (Partial).

CLPBF SharesGrow Score Overview

79/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 75/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CLPBF

CLPBF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CLPBF: +7.3%/yr revenue is, -7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CLPBF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CLPBF: Debt-to-Equity (D/E) ratio 1.4 (moderate), Current ratio is 1.61 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CLPBF: Gross margin is 65.1% (-3.7 pp trend), $14B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 75/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate CLPBF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CLPBF: Net profit margin is 13%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range66.48-116.1

Volume150

Avg Volume (30D)403

Market Cap$13.54B

Beta (1Y)0.58

Dividend Yield$3.5570

Share Statistics

EPS (TTM)16.10

Shares Outstanding$225.37M

IPO Date2000-08-09

Employees16,741

CEOLars Soren Rasmussen

Financial Highlights & Ratios

Revenue (TTM)$27.82B

Gross Profit$18.1B

EBITDA$8.32B

Net Income$3.63B

Operating Income$7.57B

Total Cash$945.2M

Total Debt$22.6B

Net Debt$21.65B

Total Assets$48.28B

Price / Earnings (P/E)4.1

Price / Sales (P/S)0.49

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryDK

ExchangeOther OTC

CurrencyUSD

ISINDK0060448595

Price Chart

CLPBF

Coloplast A/S ↗ · Other OTC

Healthcare • Medical - Instruments & Supplies

66.48 52WK RANGE 116.10

People Also View

EssilorLuxottica SA

EssilorLuxottica SA

HOYA Corporation

Becton, Dickinson and Company

Straumann Holding AG

Sysmex Corporation

Carl Zeiss Meditec AG

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message